An interventional study of Surgery in Stroke, sponsored by Tianjin Huanhu Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by Tianjin Huanhu Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.
Among the 613 studies in Stroke with a site in China, this one is the 317th largest by planned enrollment of the 432 interventional ones that give a count, is one of 71 that started in 2024, is one of 264 with no phase, reaches primary completion later than 113 of the 262 other live ones, and was the 514th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in China
Ages 18–80 · Healthy volunteers
Qingdao Central Hospital · Sites in China
Ages 18–75
Beijing Pins Medical Co., Ltd · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
613 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 72 · Phase 4 42
First in 2000; this study’s year is marked. 71 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 169 across the 432 interventional studies, 611 across the 180 observational. Of the 211 that completed or were terminated, 31 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 613 have an industry lead sponsor. The 10 most frequent:
Tianjin Huanhu Hospital is the lead sponsor of 26 studies on the registry; 20 are open to participants now.
Tianjin Huanhu Hospital has 5 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
68 of the studies in Stroke with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976152Phase 3Fudan UniversityEffect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) | 2026-12 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07002476Phase 3Shanghai East HospitalEarly Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion | 2027-03-01 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
Add all 68 to your calendar (.ics) → With an account.
Among the 613 studies in Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to evaluate the efficacy and safety of combined recanalization therapy in patients who cannot be recanalized by acute large vessel occlusive stroke. The main questions it aims to answer are:
1、Proportion of subjects with mRs score of 0-1 at 90 days after surgery
Participants will:
1、In acute large vessel occlusive stroke, if traditional means cannot be recanalized, combined recanalization surgery (including arteriotomy and thrombectomy, cerebrovascular bypass surgery) is performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Surgery
Recombined recanalization surgery
Proportion of subjects with mRs score of 0-1 at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
Changes in NIHSS score at 24 hours after surgery, 7 days after surgery, 30 days after surgery and 90 days after surgery compared with baseline;
Time frame: 90 days after recombined recanalization surgery
The mRs score changed from baseline at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
Change from baseline in MOCA score at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
Change from baseline in MMSE score at 90 days after surgery
Time frame: 90 days after recombined recanalization surgery
Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 23 months is close to that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tianjin Huanhu Hospital